osimertinib
astrazeneca
['osimertinib', 'ts,perio,i', 'adaura', 'aura ,(-laura)']
 why are we applauding a study which did not utilize a standard of care control arm? conclusions from adaura are largely meaningless as barely any patients received salvage osimertinib at progression on the control arm, which was the prevailing soc during trial enrollment period.
Medical physicist➡️MD. Passionate about everything #radonc. Focus on QoL, LR-PFS 🎯, constraints🙅‍♀️, isotoxicity ⚖️ and OS. #RadOncCalc @RadOncReview